Evolocumab in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis of efficacy and safety. [PDF]
Li S, Zhang C, Liu Y.
europepmc +1 more source
Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study. [PDF]
Gu T +7 more
europepmc +1 more source
Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care? [PDF]
Brandts J, Marx N.
europepmc +1 more source
Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]
Raone L +8 more
europepmc +1 more source
Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies. [PDF]
Katzmann JL, Laufs U.
europepmc +1 more source
Alirocumab <i>versus</i> Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis. [PDF]
Cleto AS +3 more
europepmc +1 more source
PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study. [PDF]
Akhtar W +6 more
europepmc +1 more source
Clinical observation of renal artery stenosis treated with PCSK9 inhibitor. [PDF]
Zhao F +5 more
europepmc +1 more source
Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience.
Dello Strologo A +8 more
europepmc +1 more source
Current and Future Perspectives of LDL-C Lowering Therapies 2026. [PDF]
Tada H, Sakata K, Usui S, Takamura M.
europepmc +1 more source

